Share on facebook Share on Twitter Share on Google Plus Share This
Back to Results

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia


Title AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
Therapeutic Area Leukemias (Pediatric)
Principal Investigator Michael J. Kelly, MD
Min Age 1 Years
Max Age 31 Years
Gender Both
Contact Jennifer Truong
617-636-8885
More Information https://clinicaltrials.gov/ct2/show/NCT01406756

Overview

This study will look at how effective different combinations of chemotherapy are a preventing acute lymphoblastic leukemia from coming back.

Study Details

Inclusion Criteria

  • Newly diagnosed B lymphoblastic leukemia
  • Otherwise normal organ function

Exclusion Criteria

  • No pregnant or nursing females
  • No subjects with known Hepatitis B or C infection or history of cirrhosis

Study Requirements

Subjects on this study will receive study intervention for about 2 ½ years. Subjects will come to the hospital for clinic visits, medical tests, and chemotherapy infusions just as often if they weren’t on this study. If they agree, subjects’ tissue (extra blood and bone marrow collected for clinical purposes) will be used for future research about cancer.
Nurse navigators for cancer patients at Tufts Medical Center.

Are you interested in learning more about this clinical trial?

Send us a message and we'll get back to you with more information.

Request information